

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JUL 28 CA/CAPLUS patent coverage enhanced
NEWS 3 JUL 28 EPFULL enhanced with additional legal status
information from the epoline Register
NEWS 4 JUL 28 IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 5 JUL 28 STN Viewer performance improved
NEWS 6 AUG 01 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 7 AUG 13 CA/CAPLUS enhanced with printed Chemical Abstracts
page images from 1967-1998
NEWS 8 AUG 15 CAOLD to be discontinued on December 31, 2008
NEWS 9 AUG 15 CAPLUS currency for Korean patents enhanced
NEWS 10 AUG 27 CAS definition of basic patents expanded to ensure
comprehensive access to substance and sequence
information
NEWS 11 SEP 18 Support for STN Express, Versions 6.01 and earlier,
to be discontinued
NEWS 12 SEP 25 CA/CAPLUS current-awareness alert options enhanced
to accommodate supplemental CAS indexing of
exemplified prophetic substances
NEWS 13 SEP 26 WPIDS, WPINDEX, and WPIX coverage of Chinese and
and Korean patents enhanced
NEWS 14 SEP 29 IFICLS enhanced with new super search field
NEWS 15 SEP 29 EMBASE and EMBAL enhanced with new search and
display fields
NEWS 16 SEP 30 CAS patent coverage enhanced to include exemplified
prophetic substances identified in new Japanese-
language patents
NEWS 17 OCT 07 EPFULL enhanced with full implementation of EPC2000
NEWS 18 OCT 07 Multiple databases enhanced for more flexible patent
number searching
NEWS 19 OCT 22 Current-awareness alert (SDI) setup and editing

enhanced
NEWS 20 OCT 22 WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT
Applications
NEWS 21 OCT 24 CHEMLIST enhanced with intermediate list of
pre-registered REACH substances

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:17:49 ON 20 NOV 2008

=> file caplus

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		0.21	0.21

FILE 'CAPLUS' ENTERED AT 15:18:06 ON 20 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 20 Nov 2008 VOL 149 ISS 21
FILE LAST UPDATED: 19 Nov 2008 (20081119/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s I-3050 and 35C1

4550056 I

1869 3050

24 I-3050

(I(W)3050)

11 35C1

L1 0 I-3050 AND 35C1

=> s I-3050 and aurora

4550056 I

1869 3050

24 I-3050

(I(W)3050)

4744 AURORA

506 AURORAS

4829 AURORA

(AURORA OR AURORAS)

L2 0 I-3050 AND AURORA

=> s I-3050

4550056 I

1869 3050

L3 24 I-3050

(I(W)3050)

=> s L3 and 35C1

11 35C1

L4 0 L3 AND 35C1

=> s 35C1

L5 11 35C1

=> duplcaite remove L3

DUPLCAITE IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> duplicate remove L3

PROCESSING COMPLETED FOR L3

L6 24 DUPLICATE REMOVE L3 (0 DUPLICATES REMOVED)

=> duplicate remove L5

PROCESSING COMPLETED FOR L5

L7 11 DUPLICATE REMOVE L5 (0 DUPLICATES REMOVED)

=> s L6 and antibody

L8 24 S L6

338752 ANTIBODY

407943 ANTIBODIES

539208 ANTIBODY

(ANTIBODY OR ANTIBODIES)

L9 0 L8 AND ANTIBODY

=> s L5 and antibody

338752 ANTIBODY

407943 ANTIBODIES

539208 ANTIBODY

(ANTIBODY OR ANTIBODIES)

L10 2 L5 AND ANTIBODY

=> d L10 bib abs 1-2

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:990980 CAPLUS

DN 140:40888

TI Monoclonal antibodies to Aurora A kinase and their use in the
diagnosis and treatment of cancer

IN Prigent, Claude; Martin, Anne

PA Centre National De La Recherche Scientifique Cnrs, Fr.

SO Fr. Demande, 33 pp.

CODEN: FRXXBL

DT Patent

LA French

FAN.CNT 1

	PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
	-----	----		-----	-----	
PI	FR 2840905	A1	20031219	FR 2002-7212		20020612
	FR 2840905	B1	20060707			
	CA 2489214	A1	20031224	CA 2003-2489214		20030612

WO 2003106500 A1 20031224 WO 2003-FR1772 20030612
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA,
UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003255671 A1 20031231 AU 2003-255671 20030612
EP 1511771 A1 20050309 EP 2003-760023 20030612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
JP 2006513135 T 20060420 JP 2004-513330 20030612
US 20070117163 A1 20070524 US 2005-517645 20050210
PRAI FR 2002-7212 A 20020612
WO 2003-FR1772 W 20030612

AB The present invention has as an aim a monoclonal antibody
directed against kinase aurora-A of the mammals, its process of obtaining,
as its uses within the framework of the diagnosis or the forecast of
cancers, and in pharmaceutical compns. within the framework of the
treatment of cancers. Monoclonal antibodies have been raised
against the Aurora A kinase for use in the diagnosis, prognosis, and
treatment of cancer. The monoclonal antibody 35C1
does not inhibit Aurora A kinase.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:958062 CAPLUS

DN 138:285769

TI Preparation and characterization of a human aurora-A kinase monoclonal
antibody

AU Cremet, Jean Yves; Descamps, Simon; Verite, Frank; Martin, Ann; Prigent,
Claude

CS Faculte de medecine, IFR 97 Genomique et Sante, CNRS - UMR 60611 Genetique
et Developpement, Universite de Rennes 1, Rennes, 35043, Fr.

SO Molecular and Cellular Biochemistry (2003), 243(1&2), 123-131

CODEN: MCBIB8; ISSN: 0300-8177

PB Kluwer Academic Publishers

DT Journal

LA English

AB We have developed monoclonal antibodies against the human

aurora-A serine/threonine kinase. After immunization of a mouse, a fusion was performed to obtain hybridomas that were selected because they produced Ig pos. reacting against the protein used for immunization. We isolated one particular monoclonal that we named 35C1 using a series of selective assays. The first criteria of the screen for monoclonals was an Elisa (Enzyme Linked Immunosorbant Assay) assay performed in 96-well plates against the purified recombinant histidine-tagged aurora-A. The second was a pos. Western blot against the same recombinant protein. The third criteria was a pos. western blot against an HeLa cell ext., the selected monoclonal should detect only one protein migrating at 46 kDa (kiloDalton) on SDS (Sodium Dodecyl Sulfate)-polyacrylamide gel electrophoresis. Finally, the monoclonal had to bind to duplicated centrosomes and spindle poles in human MCF7 cultured cells by indirect immunofluorescence. At this stage several monoclonals were still pos. We then increased the selectivity by searching for antibodies that were able to cross-react with the mouse aurora-A kinase both by western blot and indirect immunofluorescence. We selected and cloned the 35C1 hybridoma to produce the antibody. Further characterization of the 35C1 antibody revealed that it was able to immunoppt. the kinase, that it did not inhibit the aurora-A kinase activity and consequently could be used to measure the aurora-A kinase activity in vivo after immunopptn.

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT